Community Health Systems (CYH) Q4 2025 earnings review
Shrinking Footprint, Stalling Core: Profitability Slides as Volumes Contract
Community Health Systems reported a headline 'beat' on Net Income ($110M) that masks a deteriorating operating picture. The positive EPS was driven entirely by a $164M net gain on business sales; Adjusted EBITDA—the true measure of operating performance—fell 7.7% YoY to $395M. Most concerning is the reversal in volume trends: Same-Store Admissions turned negative (-0.3%) after showing growth earlier in the year. The 2026 guidance confirms the company is shrinking, forecasting revenue and EBITDA well below 2025 levels as divestitures shrink the top line and margin pressures persist.
🐂 Bull Case
The divestiture strategy is generating cash to repair the balance sheet. CYH redeemed $445M in high-interest 2032 notes (10.875%) and cleared remaining 2027 notes. Reduced interest expense will aid future cash flows.
For FY2025, CYH swung to a Net Income of $509M from a loss of $516M in FY2024. While driven by asset sales ($406M gain) and debt extinguishment gains ($97M), it stabilizes the equity base.
🐻 Bear Case
The recovery thesis is broken. Same-store admissions fell 0.3% YoY in Q4, a sharp deceleration from the +4.0% growth seen in Q1. Without volume leverage, the fixed-cost heavy hospital model struggles.
FY2026 guidance projects Adjusted EBITDA of $1.34B-$1.49B, significantly below the $1.526B achieved in 2025. This implies the core business isn't growing fast enough to offset the earnings lost from sold hospitals.
⚖️ Verdict: 🔴
Bearish. The 'turnaround' is heavily reliant on financial engineering (asset sales) rather than operational improvement. With same-store volumes turning negative and 2026 guidance pointing to lower earnings, the core growth story is absent.
Key Themes
Volume Recovery Stalls Out
Throughout 2025, the bull case rested on recovering volumes. That trend reversed in Q4. Same-store admissions dropped 0.3% YoY, and consolidated admissions plunged 6.6% (driven by divestitures). This weak demand environment makes margin expansion nearly impossible solely through cost cuts.
Reimbursement Headwinds
Management explicitly blamed the Q4 Adjusted EBITDA decline on 'lower net benefit from supplemental reimbursement programs' and lower volumes. This indicates that state-level funding mechanisms, which provided a tailwind earlier in the year (e.g., New Mexico/Tennessee programs mentioned in Q2/Q3), may be normalizing or facing tough comps.
Portfolio Optimization & Cash Injection
CYH is shrinking to survive. The company sold three PA hospitals (Scranton/Wilkes-Barre) and its stake in Tennova Healthcare-Clarksville, generating ~$656M in gross cash proceeds. An additional $450M sale of Crestwood Medical Center is pending. These sales are critical for servicing the debt load but permanently reduce earnings power.
Debt Management Strategy
The company is utilizing call provisions to attack its debt stack. By redeeming $445M of 10.875% notes (expensive debt) and the remaining 5.625% notes, CYH is actively managing interest expense. However, total long-term debt remains massive at $10.38B, implying leverage is still very high relative to the shrinking EBITDA base.
Consolidated Revenue Erosion
While same-store revenue eked out a 2.1% gain, total net operating revenues fell 4.9% to $3.106B. This divergence highlights the scale of the divestitures. The company is trading top-line scale for liquidity, a strategy that has limits.
Other KPIs
Decelerating. Down 7.7% YoY from $428M. The margin contracted to 12.7% from 13.1% a year ago, driven by the drop in supplemental reimbursement and negative volume leverage.
Reversing (Positive). A swing from a $70M loss in 24Q4. However, this is low-quality earnings: it includes a $164M non-cash gain on business sales. Excluding adjustments, diluted EPS was $0.00.
Accelerating. Up 23% from $216M in the prior year. FY2025 OCF hit $543M, though this remains tight relative to the $335M spent on CapEx and massive debt obligations.
Guidance
Decelerating. The midpoint ($11.8B) implies a 5.5% decline from FY2025 actuals ($12.48B). This reflects the full-year impact of hospital divestitures.
Decelerating. The midpoint ($1.415B) represents a 7.3% decline from FY2025 actuals ($1.526B). Management is not forecasting organic growth sufficient to backfill the earnings lost from asset sales.
Accelerating. Midpoint ($650M) is up ~20% vs FY2025 actuals ($543M). This assumes improved working capital management or lower cash interest/taxes, despite lower EBITDA.
Stable. Consistent with FY2025 levels ($335M actual), indicating maintenance-level spending rather than aggressive growth investment.
Key Questions
The Negative Volume Turn
Same-store admissions flipped from +1.3% in Q3 to -0.3% in Q4. Was this driven by specific payer friction, flu seasonality, or competitive losses in remaining markets?
Supplemental Reimbursement Cliff
You cited 'lower net benefit from supplemental reimbursement' as a drag on Q4 EBITDA. Is this a timing issue, or a permanent step-down in state-level support for 2026?
Organic Growth in Remaining Portfolio
With 2026 revenue guided down ~5.5% due to divestitures, what is the implied organic growth rate for the remaining assets? Are you assuming positive same-store volumes for 2026?